Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
A new study by Sandra Amaral and her team has found that children with chronic kidney disease (CKD), regardless of disease severity,...
Read Full NewsImproving Diabetic Macular Edema Care in Native American Communities: Real-World Insights and Culturally Responsive Approaches
Targeting the PI3K/AKT/PTEN Pathway to Optimize Treatment for HR+/HER2- Breast Cancer
Navigating Treatment-Associated Adverse Events and Patient-Centered Supportive Care in HR+/HER2- Breast Cancer
Optimizing Safe Administration of Novel Infusion Therapies in HR+/HER2- Advanced Breast Cancer
Optimizing Treatment Sequencing in Endocrine-Refractory HR+/HER2- Breast Cancer
Evaluating the Latest Evidence on Emerging Somatostatin Receptor Ligands for Acromegaly
Navigating Advances in Cystic Fibrosis Care
1.
Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment
2.
In advanced endometrial cancer, immunocheckpoint inhibitor-chemotherapy combination improves overall survival.
3.
First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.
4.
AI Unlocks Benefits of Prostate Cancer Treatment.
5.
Q&A: How early cancer screening could save Canada nearly half a billion dollars over patients' lifetimes
1.
From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma
2.
The Bloodstream Compass: A Comparative Clinical Review of Liquid Biopsy and AI in Predictive Oncology
3.
Obesity is a major risk factor for cancer
4.
Managing High Potassium Levels: A Comprehensive Guide to Veltassa
5.
Understanding Acute Myeloid Leukemia (AML) and Its Survival Rates
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Navigating the Complexities of Ph Negative ALL - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge